Reading Time: < 1 minute
In this issue of the Psychedelic Patent Analysis, we look at IP and exclusivity in MDMA drug development across Lykos, atai, MindMed, Arcadia, and PharmAla. We also look at Terran’s allowed claims to certain psilocybin solid forms.
Each month, we provide an interactive database of psychedelic patents that were granted, allowed, abandoned, rejected or that had responses filed.
We then provide detail and analysis on a handful of specific cases, or one deep dive.
Our monthly Psychedelic Patent Analysis is exclusively for Pα+ subscribers. Head to our Join page to learn more, or sign in to your account.
